M ore than 30,000 corneal transplantations are performed each year in the United States-more than all heart, kidney, and liver transplantations. 1 Corneal transplantation (or penetrating keratoplasty, PK) is one of the most successful of such operations in humans, with success exceeding 90%. Still, a significant number of corneal transplantations end in rejection and graft failure every year. The need for regrafting a failed transplant is one of the top two indications for corneal transplantation in many centers in the United States, competing with pseudophakic bullous keratopathy in frequency. 2 The major risk factors for rejection are prior corneal transplantation, glaucoma, and preoperative corneal vascularization. 3 Prevention of corneal neovascularization would be a pivotal step toward inhibiting graft failure and rejection.
Endothelial cell migration, proliferation, and modification of the extracellular matrix are all involved in angiogenesis. Molecules that stimulate or inhibit vessel growth modulate angiogenesis. 4 A variety of pathologic states can result from a decreased production of inhibitors or an increased production of stimulators. 4 For example, an elevated level of vascular endothelial growth factor (VEGF) is associated with the abnormal neovascularization in diabetic retinopathy. 5 The development of a biological agent to combat proangiogenic stimulation would be a useful tool. Prior attempts to inhibit rejection have included ex vivo gene therapy in a sheep corneal transplantation model. 6 Donor grafts were transduced with an adenovirusmediated delivery system with a gene encoding IL-10, which downregulates some of the steps in the cascade of cell-mediated immunity. These animals showed prolonged corneal allograft survival.
Endostatin, a 20-kDa C-terminal fragment of collagen XVIII ( Fig. 1 ) has been shown to be an endogenous inhibitor of angiogenesis and tumor growth in a hemangioendothelioma model in rats. 7 Endostatin impedes proliferation and migration by downregulating the expression of genes involved in cell growth, antiapoptosis, and angiogenesis, specifically within endothelial cells. 8 Endostatin has also been reported to inhibit cell matrix adhesion in endothelial cells and to promote a G 1 arrest through inhibition of cyclin D1. 9, 10 Angiostatin, a protein derived from proteolytic cleavage of an internal fragment of plasminogen (Fig. 1) , containing up to four kringle domains, inhibits angiogenesis-dependent tumor growth. 11, 12 Kringle-5 of plasminogen shares 46% to 57% amino acid identity to each of the four kringle domains of angiostatin and is a more potent inhibitor of basic fibroblast growth factor (bFGF)-stimulated angiogenesis than is angiostatin alone. 13 Kringle-5 acts specifically on endothelial cells by inhibiting cell migration, although the exact mechanism has not been fully elucidated.
14 Reports have implied that interactions between angiostatin and integrin ␣ v ␤ 3 (an integrin common to immature, newly synthesized vessels), and caveolin-1 may be essential components in this process. 15, 16 The angiostatic fusion protein consisting of mouse endostatin and mouse angiostatin has been shown to have a more potent biological effect than either gene product alone in an in vitro cancer model. 17 In the current study, the biologically active domains of human endostatin 18 and human kringle-5 were linked to make the fusion protein E::K-5 for the purpose of producing a protein able to inhibit both endothelial cell proliferation and migration.
Lentiviral vectors are efficient at transducing a number of target cells, have a large transgene-carrying capacity, and exhibit early-onset expression. As a result of proviral integration into the host genome, sustained long-term expression is achieved in many tissue types, including nondividing cells. 18, 19 In a previous study, we confirmed that a lentivirus containing a reporter gene transduces all cornea cell types efficiently, and expression is persistent in corneal cultures maintained up to 60 days. 20 To study the neovascularization and rejection of corneal transplants, we used a rabbit model of allogenic corneal transplantation.
Prior studies have documented a high rate of transplant rejection in rabbits with retained graft-host sutures after PK. 21 In this study we investigated the ability of a lentiviral vector to deliver a potentially antiangiogenic fusion gene to donor corneal buttons and to correlate successful transduction and grafting with postoperative neovascularization and graft failure.
METHODS

Lentivirus Production
An endostatin-kringle-5 (E::Kr5) fusion cDNA was amplified by PCR from the E::Kr5 pBlast vector (InvivoGen, San Diego, CA) using the forward primer (5ЈCTGAGGGATCCGGCGAAGGAG3Ј) containing a BamHI site and the reverse primer (5ЈCAATGTATCGGATCCTGTC-GAGCTAGC3Ј) containing a BamHI site. This fusion gene encodes 20 amino acids from the human IL-2 secretion signal, amino acids Ala 1333 to Lys 1516 from the human collagen XVIII gene (endostatin), an 8-amino-acid elastin linker motif VPGVGTAS, and amino acids Pro 466 to Asp 566 from the human plasminogen gene. The PCR fragment was digested with BamHI and ligated into the lentiviral vector pHRЈ, under the transcriptional control of the cytomegalovirus (CMV) promoter (Fig. 2) . Construction of the E::Kr5 fusion gene was confirmed by direct sequencing of the transgene insert. Replication-deficient E::Kr5 lentivirus particles were prepared as previously described. 19 Virus particles were resuspended in a minimal volume of PBS and stored at Ϫ80°C.
Viral Assay
The presence of virus particles was confirmed with a quantitative HIV-1 p24 antigen ELISA kit (ZeptoMetrix, Buffalo, NY), according to the manufacturer's instructions. To ensure the infectivity of the lentiviral reagent, 10, 50, and 100 L of virus was placed into a six-well plate of human dermal microvascular endothelial cells (HDMECs) for 20 minutes at 37°C. Medium 131 (Cascade Biologicals, Portland, OR) was then added, and cells were incubated at 37°C 5% CO 2 for 5 days, with medium changes every other day. On day 5, RNA was isolated with extraction reagent (TRIzol; Gibco-BRL, Grand Island, NY), and standard RT-PCR reactions and analyses were performed. The forward primer (5ЈTCTGAGGGTCCGCTGAAGCCCGGGG3Ј) and reverse primer (5ЈCAAATGAAGGGGCCGCAC3Ј) flanked the elastin linker region and thus amplified only the fusion transcript.
Corneal Transduction
All animal procedures were performed under Institutional Animal Care and Use Committee (IACUC)-approved protocols, which conform to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research standard for humane animal care. Sixteen 7-mm trephined donor corneas were obtained from eight New Zealand White rabbits. Each button was harvested in a sterile surgical fashion and placed in 2-mL of corneal storage medium containing chondroitin sulfate dextran medium supplemented with 100 g/mL gentamicin and 200 
Corneal Transplantation in Rabbits
General anesthesia was induced by mask administration of isoflurane. Heparin and viscoelastic were instilled by paracentesis into the anterior chamber (AC). A 7-mm Hessburg-Barron trephine (Jedmed Instruments, St. Louis, MO) was used to remove the host corneal button. A 7-mm-trephined corneal button previously treated with EK-5, eGFP, or PBS was rinsed in balanced salt solution (BSS, Alcon Laboratories, Fort Worth, TX) and grafted with 16 interrupted 7-0 nylon sutures. Subconjunctival injections (0 0.1 mL) of enrofloxacin (23 mg/mL, Baytril; Bayer Animal Health, Shawnee Mission, KS) and 40 mg/mL triamcinolone (Kenalog; Westwood Squibb Pharmaceuticals, Buffalo, NY) were given. After surgery, all animals received a single dose of topical atropine (1%) and a single dose of carprofen (Rimadyl; Pfizer, New York, NY) at 2.5 mg/kg administered subcutaneously, as well as 1 drop tobramycin twice daily for 5 days and buprenorphine (Buprenex; Reckitt Benckiser Pharmacy, Hull, UK) at 0.1 mg/kg subcutaneously as necessary. No topical steroid drops were administered after surgery.
Measurement of Neovascularization and Evaluation of Graft Rejection
Neovascularization was followed by slit lamp examinations on postoperative days 5, 9, 12, 14, 16, 24, 28, and 36. Measurements of neovascularization were made with a portable slit lamp by a single masked observer, an ophthalmologist. Vessel growth onto the clear cornea was noted in millimeters and number of clock hours. Neovascularization was quantified by calculating the wedge-shaped area of vessel growth with the formula:
, where R is the total radius and R2 is the radius from the center to the border of vessel growth. Graft rejection was evaluated by portable slit lamp. Graft failure was judged by the presence of persistent corneal graft edema with opacification of 100% of the graft. Serial photographs of the cornea were taken. Animals were killed on postoperative days 9, 21, 30, and 40. Fresh corneal tissue was placed in either extraction reagent (TRIzol; Gibco-BRL) for RT-PCR or formalin for histopathologic study.
RESULTS
A fusion cDNA coding for the 20 amino acids of human IL-2 secretion signal, human endostatin (derived from the 184 amino acids of the carboxyl terminus of collagen XVIII), an 8-amino-acid elastin linker sequence, and the 101 amino acids of human plasminogen (corresponding to the fifth kringle domain) was successfully cloned into the pHRЈ CMV-IRES-eGFP vector. Quantitative ELISA confirmed presence of virus particles and based on standard curve interpolation, 230 pg/mL of antigen was detected, correlating to approximately 10 8 virus particles/mL (Zeptometrix). Transcription of the fusion gene was verified by RT-PCR of transduced HDMECs (data not shown).
Postoperative corneal neovascularization was significantly lower in E::K-5 lentivirus-treated eyes than in either eGFP lentivirus-or PBS-treated control eyes on postoperative days 5, 12, 14, 16, 18, 24, 28, and 36 (Fig. 3) .
All PBS-and all eGFP lentivirus-treated corneas exhibited neovascular arborization into the graft bed (Fig. 4B-D, 4G ). Vascularization in all control animals was relatively unchanged after postoperative day 9. None of the 10 E::K-5-treated corneas had new vessels extending into the graft (Fig. 4E, 4F) . Three of 3 PBS-treated and 2 of 3 eGFP-treated corneas exhibited corneal opacification and graft failure (Figs. 4B, 4D, 4G ), whereas none of the 10 E::K-5-treated grafts completely opacified or failed by postoperative day 39 (Fig. 4F) . PBS-treated control corneas exhibited graft failure by postoperative days 14 and 18, and eGFP-treated corneas by day 24, with the exception of one eGFP-treated control, which remained stable for the duration of the experiment (day 36). All five grafts tested by RT-PCR for the presence of fusion gene transcripts were positive on postoperative days 30 and 40 (Fig. 5A , 5B). All control and nonsurgical eyes were negative, according to fusion gene RT-PCR.
Analysis of serial sections revealed more neovascularization and basophilic inflammatory infiltrates in control eyes than in 
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E::K-5-treated or nonsurgical eyes. Histopathologic study of a site of retained suture, often the location of an inflammatory infiltrate, was void of inflammatory cells in the examined E::K-5-treated cornea (Fig. 6C) .
DISCUSSION
The success of corneal transplantation has expanded the indications for this surgery and has increased the number of keratoplasties performed annually. Despite advances in corneal transplantation, such as enhanced storage media and improved donor requirements, graft rejection remains a major problem. 22 A major risk factor for graft rejection is neovascularization of the recipient corneal bed, the graft-host interface, or subsequently of the graft itself. The development of new blood vessels extending into the graft is associated with high levels of inflammatory cells, plasma proteins, and cytokines within the graft and is often a presage of rejection and failure. Believing that corneal neovascularization promotes rejection, investigators have long sought medical or surgical approaches to abort the process. We describe a successful approach to inhibiting the development of post-PK neovascularization in a rabbit model. This approach is based on the ability of lentiviral vectors to transduce corneal tissues ex vivo, with genes known to be antiangiogenic in animal models of tumor angiogenesis. We tested a Treatment of corneal buttons with E::K-5 by lentiviral vector prevented new vessel growth onto the donor graft in all treated corneas. Histologic study revealed a marked decrease in inflammation in E::K-5-treated corneas, including the areas around retained sutures, a commonly inflamed area. Furthermore, there was no evidence of graft failure, as measured by persistent corneal edema and corneal opacification in E::K-5-treated corneas, whereas five of six control corneas exhibited evidence of opacification and failure.
Corneas expressing E::K5 are less vascularized and less inflamed than control corneas, however, the mechanism of inhibition is not clear. Disruption of ␣ v ␤ 3 integrin distribution, expression of caveolin-1, or levels of cyclin D1 or changes in the levels of tyrosine phosphorylation of focal adhesion kinase and paxillin may independently or in combination have a role in this result. 9, 10, 15, 16 The ability of the fusion protein E::K-5 to retard new blood vessel growth may be augmented by its potentially bifunctional structure. Endostatin has been shown to inhibit new vessel growth in solid tumors in a rat hemangioendothelioma model. 7 Kringle-5 is a specific inhibitor of endothelial cell proliferation in bovine capillary cells and prevents migration of endothelial cells in a number of cell cultures stimulated by bFGF.
14 Endostatin and angiostatin proteins given together have been shown to cause more regression of blood vessels and ovarian cancer cells in an experimental model, than when administered individually. 23, 24 Similarly, these two proteins, when given together in an Fc-angiostatin plus Fc-endostatin combination, resulted in a significant reduction of tumor size in Ripa1-Tag2 mice; given separately, they had a markedly reduced effect. 25 We wanted to test a potentially bifunctional protein that combines the antiangiogenic domains of collagen XVIII and plasminogen, as an inhibitor of corneal angiogenesis.
Although the lentiviral vectors used are replication defective, questions about the safety of genetic transduction are important and appropriate. Transduction of corneal tissue ex vivo is an attractive alternative to somatic in vivo therapy. Inducible control of transgene expression may also be beneficial. Tetracycline-regulated promoters have been used in the past as a system for controlling gene expression by exogenous administration of tetracycline and should be evaluated. 26, 27 Our data suggest that ex vivo lentiviral transduction of donor corneal tissue with a fusion antiangiogenic gene, before PK, may increase the likelihood of long-term graft survival and be a useful surgical adjunct. 
